StockData
Inhibikase Therapeutics, Inc. logo

Inhibikase Therapeutics, Inc. (IKT) stock

IKTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 8/30
$1.38−0.07 (-4.83%)

Close on Nov 17, 2026Market cap $192.56MP/E –Yield –

Inhibikase Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Inhibikase Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $38.24M, up 40.8% year over year. For fiscal 2025 it was $29.79M, up 73.1% from the year before. The highest annual figure on record is $29.79M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$29.79M+73.1%
FY2024Dec 31, 2024$17.21M+26.4%
FY2023Dec 31, 2023$13.62M+13.2%
FY2022Dec 31, 2022$12.03M+6.0%
FY2021Dec 31, 2021$11.36M+1170.9%
FY2020Dec 31, 2020$893.80K–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$13.39M+154.1%
Q1 FY2026Mar 31, 2026$10.84M+3.1%
Q4 FY2025Dec 31, 2025$6.36M-11.6%
Q3 FY2025Sep 30, 2025$7.65M+82.6%
Q2 FY2025Jun 30, 2025$5.27M+71.4%
Q1 FY2025Mar 31, 2025$10.51M+282.1%
Q4 FY2024Dec 31, 2024$7.19M+139.5%
Q3 FY2024Sep 30, 2024$4.19M+29.9%
Q2 FY2024Jun 30, 2024$3.08M-32.2%
Q1 FY2024Mar 31, 2024$2.75M-3.6%
Q4 FY2023Dec 31, 2023$3.00M-1.7%
Q3 FY2023Sep 30, 2023$3.23M+8.2%
Q2 FY2023Jun 30, 2023$4.54M+52.1%
Q1 FY2023Mar 31, 2023$2.85M-5.4%
Q4 FY2022Dec 31, 2022$3.05M+28.2%
Q3 FY2022Sep 30, 2022$2.98M+22.6%
Q2 FY2022Jun 30, 2022$2.98M+1214.1%
Q1 FY2022Mar 31, 2022$3.02M+2402.3%
Q2 FY2021Jun 30, 2021$2.38M+805.3%
Q1 FY2021Mar 31, 2021$2.43M+759.0%
Q4 FY2020Dec 31, 2020$226.94K–
Q3 FY2020Sep 30, 2020$120.57K–
Q2 FY2020Jun 30, 2020$263.18K–
Q1 FY2020Mar 31, 2020$283.11K–

More Inhibikase Therapeutics figures

See a number that looks wrong?